501 related articles for article (PubMed ID: 25253414)
1. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
4. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
8. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
9. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
[TBL] [Abstract][Full Text] [Related]
12. Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.
Hildebrandt G; Zierski J; Csecsei G; Mueller HW; Stracke H
Acta Neurochir (Wien); 1992; 117(3-4):160-5. PubMed ID: 1414517
[TBL] [Abstract][Full Text] [Related]
13. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy for acromegaly.
Newman CB
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
17. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus.
Arihara Z; Sakurai K; Yamada S; Murakami O; Takahashi K
Tohoku J Exp Med; 2008 Dec; 216(4):325-9. PubMed ID: 19060447
[TBL] [Abstract][Full Text] [Related]
19. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.
de Herder WW; Uitterlinden P; van der Lely AJ; Hofland LJ; Lamberts SW
Eur J Endocrinol; 1995 Aug; 133(2):195-9. PubMed ID: 7544670
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
